Dashboard
Manage Tickers

RMD RESMED INC

NYSE resmed.com


$ 259.40 $ -5.77 (-2.18 %)    

Friday, 24-Oct-2025 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 259.49
$ 266.83
$ 258.40 x 10
$ 265.80 x 20
$ 259.41 - $ 266.97
$ 199.07 - $ 293.81
1,110,285
na
37.99B
$ 0.99
$ 27.12
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-K
2 04-23-2025 03-31-2025 10-Q
3 01-31-2025 12-31-2024 10-Q
4 10-24-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-K
6 04-25-2024 03-31-2024 10-Q
7 01-25-2024 12-31-2023 10-Q
8 10-26-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-K
10 04-28-2023 03-31-2023 10-Q
11 01-27-2023 12-31-2022 10-Q
12 10-28-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-K
14 04-28-2022 03-31-2022 10-Q
15 01-27-2022 12-31-2021 10-Q
16 10-28-2021 09-30-2021 10-Q
17 08-17-2021 06-30-2021 10-K
18 04-30-2021 03-31-2021 10-Q
19 01-29-2021 12-31-2020 10-Q
20 10-30-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-K
22 05-01-2020 03-31-2020 10-Q
23 01-31-2020 12-31-2019 10-Q
24 10-25-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-K
26 05-03-2019 03-31-2019 10-Q
27 02-01-2019 12-31-2018 10-Q
28 10-26-2018 09-30-2018 10-Q
29 08-17-2018 06-30-2018 10-K
30 04-27-2018 03-31-2018 10-Q
31 01-24-2018 12-31-2017 10-Q
32 10-27-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-K
34 04-28-2017 03-31-2017 10-Q
35 01-25-2017 12-31-2016 10-Q
36 10-28-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-K
38 04-29-2016 03-31-2016 10-Q
39 01-28-2016 12-31-2015 10-Q
40 10-27-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

what-9-analyst-ratings-have-to-say-about-resmed
What 9 Analyst Ratings Have To Say About R...
10/21/2025 13:02:18

slb-to-rally-around-44-here-are-10-top-analyst-forecasts-for-tuesday
SLB To Rally Around 44%? Here Are 10 Top A...
10/21/2025 13:02:06

morgan-stanley-maintains-overweight-on-resmed-raises-price-target-to-304
Morgan Stanley Maintains Overweight on Res...
10/21/2025 11:53:18

Morgan Stanley analyst Sean Laaman maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $298 to $304.

resmed-stock-a-deep-dive-into-analyst-perspectives-9-ratings
ResMed Stock: A Deep Dive Into Analyst Per...
09/18/2025 20:00:54

this-progressive-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Progressive Analyst Is No Longer Bull...
09/18/2025 14:00:34

this-target-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday
This Target Analyst Begins Coverage On A B...
09/18/2025 11:30:38

citigroup-initiates-coverage-on-resmed-with-buy-rating-announces-price-target-of-330
Citigroup Initiates Coverage On ResMed wit...
09/18/2025 11:21:32

Citigroup analyst Laura Sutcliffe initiates coverage on ResMed (NYSE:RMD) with a Buy rating and announces Price Target of $330.

the-analyst-verdict-resmed-in-the-eyes-of-8-experts
The Analyst Verdict: ResMed In The Eyes Of...
08/01/2025 19:03:05

resmed-analysts-increase-their-forecasts-after-strong-q2-earnings
ResMed Analysts Increase Their Forecasts A...
08/01/2025 18:16:26

mizuho-maintains-outperform-on-resmed-raises-price-target-to-290
Mizuho Maintains Outperform on ResMed, Rai...
08/01/2025 16:38:15

Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $270 to $290.

stifel-maintains-hold-on-resmed-raises-price-target-to-270
Stifel Maintains Hold on ResMed, Raises Pr...
08/01/2025 16:14:59

Stifel analyst Jonathan Block maintains ResMed (NYSE:RMD) with a Hold and raises the price target from $240 to $270.

rbc-capital-maintains-outperform-on-resmed-raises-price-target-to-300
RBC Capital Maintains Outperform on ResMed...
08/01/2025 16:14:12

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $294 to $300.

ubs-maintains-buy-on-resmed-raises-price-target-to-325
UBS Maintains Buy on ResMed, Raises Price ...
08/01/2025 15:50:17

UBS analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and raises the price target from $285 to $325.

apple-to-rally-around-16-here-are-10-top-analyst-forecasts-for-friday
Apple To Rally Around 16%? Here Are 10 Top...
08/01/2025 13:58:17

keybanc-maintains-overweight-on-resmed-raises-price-target-to-298
Keybanc Maintains Overweight on ResMed, Ra...
08/01/2025 13:06:55

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $274 to $298.

piper-sandler-maintains-neutral-on-resmed-raises-price-target-to-270
Piper Sandler Maintains Neutral on ResMed,...
08/01/2025 12:20:36

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $248 to $270.

resmed-q4-adj-eps-255-beats-246-estimate-sales-1348b-beat-1321b-estimate
ResMed Q4 Adj. EPS $2.55 Beats $2.46 Estim...
07/31/2025 20:05:36

ResMed (NYSE:RMD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 by 3.83 per...

meta-microsoft-power-wall-street-to-new-records-despite-inflation-jump-whats-moving-markets-thursday
Meta, Microsoft Power Wall Street To New R...
07/31/2025 17:21:14

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

Core News & Articles
'A Pill for Sleep Apnea Could Be on the Ho...
07/23/2025 18:55:47

https://www.nytimes.com/2025/07/23/well/apnimed-sleep-apnea-clinical-trial-ad109.html

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION